Skip to main content
    A

    Ardelyx Inc (ARDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.02 (-0.65%)

    Market Cap: $776.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ardelyx Inc (ARDX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ardelyx (ARDX) trades at 1.6x sales and 4.7x book value. Its P/S of 1.6x is below its 5-year median of 6.9x. Its forward P/E is 51.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E51.3x
    Price to sales1.6x
    Price to book4.7x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 84.3% below 10.2x and its P/B is 17.5% above 4.0x.

    MultipleCurrent5-year median10-year median
    P/S1.6x6.9x10.2x
    P/B4.7x7.4x4.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 108 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 3.5x in 2025 to 93.2x in 2019. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$5.833.5x8.5x
    2024$5.073.6x7.1x
    2023$6.2010.9x8.2x
    2022$2.8510.2x5.6x
    2021$1.1010.9x1.5x
    2020$6.4776.6x4.7x
    2019$7.5193.2x2.8x
    2018$1.7933.4x1.0x
    2017$6.607.7x2.3x
    2016$14.20N/A3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ARDX

    What is ARDX's forward P/E ratio?

    Ardelyx has a forward P/E ratio of 51.3x.

    Is ARDX stock overvalued?

    GNG's valuation label for ARDX is Undervalued.

    What is ARDX's price to sales ratio?

    Ardelyx has a price to sales ratio of 1.6x.